ArticleCirculation research2024
SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice.
Abstract readLetter
In one paragraph
Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors.Nature reviews. Cardiology · 2026Article
- Metabolic determinants of autoimmune kidney diseases.Nature reviews. Nephrology · 2026Review
- Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. Reply.The Journal of clinical investigation · 2026Article
- Article
- Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression.Basic research in cardiology · 2026Article
- Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.Cardiovascular diabetology · 2026Article
- SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.The Journal of clinical investigation · 2026Article
- Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices.bioRxiv : the preprint server for biology · 2026Article
- Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review.Kidney360 · 2026Review
- Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy.bioRxiv : the preprint server for biology · 2026Article
- Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.Nature reviews. Cardiology · 2025Review
- Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.Pharmacological reviews · 2025Review
- Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction.Atherosclerosis · 2025Article
- Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.Nature reviews. Cardiology · 2025Review
- Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure.Scientific reports · 2025Article
- Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Empagliflozin to Prevent Doxorubicin Cardiotoxicity.JACC. CardioOncology · 2025Article
- Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far?Frontiers in clinical diabetes and healthcare · 2025Review
- Inhibition of the NaFrontiers in immunology · 2025Article
- Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues.The Journal of clinical investigation · 2024Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Justin H BergerDivision of Cardiology, Cardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA (J.H.B., D.P.K.).ORCID 0000-0002-1454-0097
Timothy R MatsuuraDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
Caitlyn E BowmanDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).ORCID 0000-0003-2310-581X
Renee TaingDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
Jiten PatelDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
Ling LaiDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
Teresa C LeoneDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
Jeffrey D ReaganAmgen Research, Cardiometabolic Disorders, South San Francisco, CA (J.D.R., S.M.H.).
Saptarsi M HaldarAmgen Research, Cardiometabolic Disorders, South San Francisco, CA (J.D.R., S.M.H.).
Zoltan AranyDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).ORCID 0000-0003-1368-2453
Daniel P KellyDivision of Cardiology, Cardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA (J.H.B., D.P.K.).
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MTraining Program in Cardiovascular Biology and MedicineT32HL007843 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Sharlene M Day · 1996 to 2026
$11.0MREGULATION OF FATTY ACID OXIDATION DURING CARDIAC GROWTHR01HL058493 · NHLBI · WASHINGTON UNIVERSITY · PI KELLY, DANIEL PATRICK · 1998 to 2024
$10.6MPediatric Scholars ProgramK12HD043245 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ST. GEME, JOSEPH W. · 2003 to 2022
$7.4MProbing the Role of Mitochondrial Short-chain Carbon Homeostasis in the Hypertrophied and Failing HeartR01HL128349 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUOIO, DEBORAH M · 2016 to 2024
$6.1MTargeting Ketone Metabolism as a Novel Heart Failure TherapyR01HL151345 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KELLY, DANIEL PATRICK, RECCHIA, FABIO A · 2020 to 2023
$3.2MVevo 2100 Imaging SystemS10OD016393 · OD · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2013 to 2013
$256kAmerican Heart Association-American Stroke Association 24CDA1269277NCI NIH HHS P30 CA016520NHLBI NIH HHS R01 HL058493NHLBI NIH HHS R01 HL128349NHLBI NIH HHS R01 HL151345NHLBI NIH HHS T32 HL007843NICHD NIH HHS K12 HD043245NIH HHS S10 OD016393
Abstract
PubMed holds no abstract for this paper.
Indexed as
Heart FailureSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsAnimalsMaleMiceMice, Inbred C57BLMice, KnockoutStroke VolumeSlc5a2 protein, mouseSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsdrug therapyexperimental animal modelsheart failure, systolicketosisventricular remodeling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.